Bruce Leuchter

Bruce currently serves as the President & CEO of Neurvati Neurosciences, a Blackstone Life Sciences company. He brings deep-rooted, wide-ranging experience to this role spanning clinical neuropsychiatry, biotechnology equity research, healthcare investment banking, and drug development. Across his many roles in academia, clinical medicine, financial services, and industry, Bruce has maintained a passion for knowledge and serving patients and families in need.

A physician by training and neuropsychiatrist by specialty, Bruce completed residency training in Neurology and Psychiatry at New York Presbyterian Hospital and Weill Cornell Medical College and is a Diplomate of the American Board of Psychiatry and Neurology. Bruce served as Director of Clinical Neuropsychiatry at Weill Cornell Medical College and maintains a voluntary faculty appointment in the Department of Psychiatry. Previously, Bruce was a Partner at PJT Partners where he provided M&A and capital markets advisory services to biotechnology companies. He also held roles in equity research and investment banking at Goldman Sachs and Credit Suisse, respectively.

Bruce is a Co-founder and Senior Advisor of Click Therapeutics, a biotechnology company developing software as prescription medical therapeutics. He serves as a member of the Scientific Advisory Committee for the Daedelus Fund for Innovation at Weill Cornell Medical College, as a member of the Life Science Institute Leadership Council and Michigan Drug Discovery Advisory Board at The University of Michigan, and as a Business Advisory Board member at FOXG1 Research Foundation.